Skip to content

Meet with Ontada

at ASH Annual Meeting 2025

 

 

December 6 - 9 | Orlando (Orlando Convention Center)

VISIT US AT BOOTH 106

 

Icon

ASH is rapidly approaching, and we look forward to connecting. To meet with us at ASH and learn more about Ontada's real-world oncology data, research offerings and provider education solutions, fill out the form or stop by Booth #106 to chat.

​For information about our research being presented, simply scroll down on this page.

ASH 2025 presentations

Real-World (RW)Treatment (Tx) Patterns,  Factors Associated with Discontinuation and Toxicity Across Covalent BTK Inhibitors (cBTKis) in First-Line (1L) Tx of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) 

Poster

Saturday, Dec 6, 5:30 – 7:30 p.m.

Presenter: John M. Burke, MD

Authors: John M. Burke, Enrico de Nigris, Yunfei Wang, Kathleen M. Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Siyang Leng, Ira Zackon

Presentation ID: 2111

Maintaining higher hemoglobin levels is associated with improved overall survival in Myelodysplastic Syndromes (MDS): A real-world retrospective analysis of electronic health records from a US community setting over the past 20 years 

Poster

Saturday, Dec 6, 5:30 – 7:30 p.m.

Presenter: Ira Zackon, MD

Authors: Zhaohui Su, Matthew Whitesell, Lisa Herms, Jessica Paulus, Ira Zackon 

Presentation ID: 2095

Correlation between Real-World (RW) Progression-Free Survival (rwPFS) and Overall Survival (OS) among Patients (Pts) with First-Line (1L) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Covalent Bruton Tyrosine Kinase Inhibitors (cBTKis) or B-Cell Lymphoma 2 Inhibitors (BCL2is) 

Poster

Sunday, Dec 7, 6:00 – 8:00 p.m.

Presenter: Ira Zackon, MD

Authors:  John M. Burke, Enrico de Nigris, Yunfei Wang, Kathleen M. Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Inkyu Kim, Siyang Leng, Ira Zackon 

Presentation ID: 3888

Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network 

Poster

Monday, Dec 8, 6:00 – 8:00 p.m.

Presenter: Ira Zackon, MD

Authors: Matthew Whitesell, Zhaohui Su, Lisa Herms, Janet Espirito, Jessica Paulus, Ira Zackon 

Presentation ID: 5857

Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting 

Poster

Monday, Dec 8, 6:00 – 8:00 p.m.

Presenter: Ira Zackon, MD

Authors: Ira Zackon, Helen Engle, Lisa Herms, Janet Espirito, Zhaohui Su 

Presentation ID: 5190

ONLINE PUBLICATIONS

Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting 

Authors:

Ping Shi, Kathleen Aguilar, Zhaohui Su, Lisa Herms, Junxin Shi, Jessica Paulus, Ira Zackon 

Real-world duration of therapy with erythropoietic stimulating agents is predictive of overall survival in Myelodysplastic Syndromes (MDS) 

Authors:

Robert Reid, Rosa Banuelos, Lisa Herms, Janet Espirito, Ira Zackon

Enhancing real-world data (RWD) quality in oncology: Implementation of the QCARD initiative in a large US oncology electronic health record (EHR)-derived database for research and regulatory decision-making 

Authors:

Zhaohui Su, Lisa Herms, Aniketh Talwai, Jessica Paulus, Robyn Harrel, Amy O'Sullivan, Janet Espirito 

Real-World Hematologic Response and Treatment Patterns among patients with Polycythemia Vera (PV) Treated with Ropeginterferon Alfa-2b (ropeg)                      

Authors:

Malcolm Charles, Zhaohui Su, Kat Aguilar, Robert Reid, Ira Zackon, Drew Bernstein, Stefanie Cribb, Edward Jefford, Paul Walden, Kyle Downey 

Meet Our Team at ASH 2025

Reach out to our team for an ASH meetup or fill out our form. We look forward to seeing you in Orlando!

 

Learn more about Ontada solutions